Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Special Report
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?By Jeffrey Neal Johnson. Posted: 4/7/2026. 
Key Points
- Abbott's Medical Devices division continues to accelerate, demonstrating the underlying strength within the company's largest business segment.
- Abbott's impressive history of consecutive dividend increases underscores its commitment to consistently rewarding long-term shareholders.
- Strategic acquisitions are positioning Abbott to lead in new high-growth healthcare sectors, securing a powerful pipeline for future expansion.
- Special Report: Elon Musk already made me a “wealthy man”
In the world of investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories (NYSE: ABT), a diversified healthcare powerhouse and a member of the elite dividend kings. For decades, investors have relied on Abbott for steady growth and dependable income. That long-standing reputation makes its recent performance all the more striking.
For a moment…
Forget about Trump’s ties to Israel.
Forget about reports of Iran’s nuclear program.
Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason. Click here to find out what it is.
Abbott Laboratories' stock price recently touched its 52-week low, closing just above $100 in the last trading days of March. This sharp downturn has left many wondering whether the foundation of this industry leader is cracking. A closer look at Abbott Laboratories' current situation suggests there may be a disconnect between market sentiment and operational reality. The key question for investors is whether the market's pessimism is justified or whether a compelling long-term value opportunity has emerged. Separating the Signal From the NoiseAbbott's recent decline stems from two main sources. The first is an internal headwind in its Nutrition segment. Abbott Laboratories' fourth-quarter 2025 earnings report showed a 9.1% organic sales drop in Nutrition, largely driven by market-share losses in the U.S. pediatric business and pricing dynamics that constrained volume. Management has been candid about the issue and outlined a clear turnaround plan: price and promotion initiatives plus a pipeline of at least eight new product launches in 2026, with a forecasted return to growth in the second half of the year. The second factor is external and macro in nature. The market has been rotating capital away from defensive sectors like the healthcare sector into higher-beta areas such as artificial intelligence (AI) and the energy sector. That broad rotation has put pressure on many fundamentally sound healthcare companies, including Abbott, for reasons largely unrelated to their individual performance or long-term prospects. Abbott’s Engine Room Is Running StrongWhile Nutrition navigates a short-term recovery, Abbott's core operations remain robust, led by its largest and most profitable division: Medical Devices. That segment is not only stable but accelerating, posting 10.4% organic growth in the most recent quarter. The company's diversified model provides a powerful counterbalance to the isolated weakness in Nutrition, and the health of the business is most apparent in these high-performing areas.
Medical Devices: The Medical Devices business is gaining momentum, fueled by market-leading innovation in critical care areas. Diabetes Care: The FreeStyle Libre franchise of continuous glucose monitors (CGM) remains a growth phenomenon. The line, which allows users to track glucose levels without routine fingersticks, generated over $7.5 billion in sales in 2025 and is a major driver of Abbott's sustained success. Cardiovascular Leadership: Abbott is also a dominant player in cardiovascular health. Its Electrophysiology business grew at a double-digit rate, and Structural Heart posted strong organic growth of 8.7%. This strength stems from best-in-class products like MitraClip and TriClip, which offer minimally invasive valve-repair solutions, and from a pipeline that includes the recently FDA-approved Volt PFA System for treating atrial fibrillation. Abbott is also pursuing strategic growth through the acquisition of Exact Sciences, a leader in non-invasive cancer screening and diagnostics best known for its Cologuard test. That deal would immediately expand Abbott's footprint into the fast-growing market for cancer diagnostics, adding a high-growth vertical that could become a meaningful revenue contributor over time. Professional analysts appear to share this bullish view. Wall Street maintains a Moderate Buy consensus rating on the stock. The average 12-month price target is $135.47, implying upside of roughly 30% from current levels and signaling a belief that the stock is undervalued. A Bedrock of Reliability for Income InvestorsFor long-term investors focused on income, Abbott's dividend is particularly attractive. Abbott is a member of the S&P 500 Dividend Kings, an exclusive group of companies that have increased their dividend for at least 50 consecutive years. That track record reflects a deep commitment to returning capital to shareholders across market cycles. The recent decline in Abbott's stock price benefits new investors by boosting the dividend yield. At current levels, Abbott offers a yield of about 2.5%, allowing investors to capture a higher income rate from this historically reliable payer. The dividend's safety is notable: the payout ratio is about 68% of earnings, while the dividend accounts for only roughly 37% of the company's cash flow, indicating ample coverage and room for future increases. A Disconnect Between Price and ValueCurrent market sentiment around Abbott appears disconnected from the company's underlying business momentum. Temporary headwinds in a single division and a broad market rotation have depressed the stock price, yet Abbott's core growth engines are accelerating. Its dominant Medical Devices division continues to deliver, the dividend remains a bedrock of reliability, and catalysts such as the Exact Sciences acquisition could provide meaningful upside. For investors with a long-term horizon, the present valuation suggests a noteworthy gap between price and fundamental value that deserves careful consideration. |
